Valuation: Cerus Corporation

Market Cap 474M 410M 383M 350M 660M 45.17B 670M 4.49B 1.76B 22.6B 1.78B 1.74B 75.26B P/E 2026 *
-58.8x
P/E 2027 * -470x
Enterprise Value 474M 410M 383M 350M 660M 45.17B 670M 4.49B 1.76B 22.6B 1.78B 1.74B 75.26B EV / Sales 2026 *
2.05x
EV / Sales 2027 * 1.8x
Free-Float
96.49%
Yield 2026 *
-
Yield 2027 * -
1 day+3.62%
1 week+13.26%
Current month+13.26%
1 month-21.96%
3 months-3.37%
6 months+9.19%
Current year+18.20%
1 week 2.06
Extreme 2.065
2.47
1 month 2.06
Extreme 2.06
3.29
Current year 1.62
Extreme 1.62
3.47
1 year 1.15
Extreme 1.15
3.47
3 years 1.12
Extreme 1.12
3.47
5 years 1.12
Extreme 1.12
8.06
10 years 1.12
Extreme 1.12
8.87
Manager TitleAgeSince
Chief Executive Officer 51 2026-06-30
Chief Tech/Sci/R&D Officer 82 2015-06-30
Director of Finance/CFO 54 2009-05-03
Director TitleAgeSince
Chairman 59 2026-03-15
Director/Board Member 72 2014-03-23
Director/Board Member 51 2026-06-30
Date Insider Type Main position Quantity % Market Cap.
7/16/26 Sell

Chief Executive Officer

-16,666 0.0083%
7/1/26 Free

Chief Executive Officer

924,215 0.4613%
6/30/26 Free

Chief Financial Officer

-97,276 0.0485%
Change 5-day change 1-year change 3-year change Capi.($)
+4.89%+13.26%+95.58%+27.49% 474M
+1.32%-0.01%-9.43%+20.54% 130B
-0.67%-7.64%-17.68%-1.65% 12.63B
+1.09%+6.05%+108.23%+145.40% 10.61B
+0.30%-3.14%-42.48%-67.21% 4.7B
-0.79%+2.31%-24.77%+36.42% 2.7B
-0.18%+16.27%-23.75%-75.39% 1.74B
+0.98%+1.79%-14.30%-12.44% 1.69B
+0.69%-0.24%-33.31%-31.93% 1.66B
Average +0.73%+4.60%+4.23%+4.58% 18.47B
Weighted average by Cap. +0.68%+3.71%-3.87%+22.76%

Financials

2026 *2027 *
Net sales 230M 200M 187M 170M 321M 21.98B 326M 2.19B 858M 11B 866M 847M 36.63B 264M 228M 213M 195M 367M 25.13B 373M 2.5B 981M 12.57B 989M 968M 41.87B
Net income -7.9M -6.84M -6.39M -5.84M -11.01M -753M -11.18M -74.96M -29.41M -377M -29.66M -29.02M -1.26B -769K -666K -622K -569K -1.07M -73.34M -1.09M -7.3M -2.86M -36.69M -2.89M -2.82M -122M
Net Debt - -
Logo Cerus Corporation
Cerus Corporation is a biomedical products company. The Company is focused on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The INTERCEPT Blood System, which is based on its proprietary technology for controlling biological replication, is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. Its INTERCEPT Blood System is intended for use with blood components and certain of their derivatives: platelets, plasma, red blood cells and to produce INTERCEPT Fibrinogen Complex (IFC), and pathogen reduced plasma, cryoprecipitate reduced. The INTERCEPT Blood System for Cryoprecipitation uses its plasma system to produce IFC for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. In addition, the INTERCEPT Blood System for Cryoprecipitation is used to produce pathogen reduced plasma, cryoprecipitate reduced.
Employees
268
Date Price Change Volume
26-08-10 $2.455 +4.47% 1,289,371
26-08-07 $2.350 +1.29% 3,484,714
26-08-06 $2.320 +2.20% 2,584,688
26-08-05 $2.270 +3.65% 3,261,941
26-08-04 $2.190 +1.86% 6,258,706
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
2.350USD
Average target price
4.500USD
Spread / Average Target
+91.49%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CERS Stock